Anxiogenic and stressor effects of the hypothalamic neuropeptide RFRP-3 are overcome by the NPFFR antagonist GJ14

Endocrinology (United States)

Volumn 156, Issue 11, 2015, Pages 4152-4162

  Kim, Joon S ^a   Brownjohn, Phil W ^a   Dyer, Blake S ^b,c   Beltramo, Massimiliano ^d   Walker, Christopher S ^e   Hay, Debbie L ^e   Painter, Gavin F ^b   Tyndall, Joel D A ^a   Anderson, Greg M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c CALLAGHAN INNOVATION   (New Zealand)

^d CEMAGREF   (France)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; CORTICOSTERONE; G PROTEIN COUPLED RECEPTOR 54; GJ 14; NEUROPEPTIDE; RFAMIDE RELATED PEPTIDE 3; UNCLASSIFIED DRUG; NEUROPEPTIDE FF RECEPTOR; NEUROPEPTIDE RECEPTOR; RFAMIDE PEPTIDE;

ANIMAL CELL; ANXIETY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORTICOSTERONE RELEASE; FEMALE; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIGAND BINDING; MALE; NERVE CELL; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; DRUG THERAPY; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CHO CELLS; CORTICOSTERONE; CRICETULUS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; NEUROPEPTIDES; PITUITARY-ADRENAL SYSTEM; RECEPTORS, NEUROPEPTIDE; STRESS, PSYCHOLOGICAL;

EID: 84946094422     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1532     Document Type: Article

References (41)

1. Liu Q, Guan X-M, Martin WJ, et al. Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J Biol Chem. 2001;276: 36961-36969.
2. Roumy M, Zajac J-M. Neuropeptide FF, pain and analgesia. Eur J Pharmacol. 1998;345:1-11.
3. Tsutsui K, Saigoh E, Ukena K, et al. A novel avian hypothalamic peptide inhibiting gonadotropin release. Biochem Biophys Res Commun. 2000;275:661-667.
4. Hinuma S, Shintani Y, Fukusumi S, et al. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol. 2000;2:703-708.
5. Bentley GE, Tsutsui K, Kriegsfeld LJ. Recent studies of gonadotro-pin-inhibitory hormone (GnIH) in the mammalian hypothalamus, pituitary and gonads. Brain Res. 2010;1364:62-71.
6. Glanowska KM, Burger LL, Moenter SM. Development of gonad-otropin-releasing hormone secretion and pituitary response. J Neu-rosci. 2014;34:15060-15069.
7. Kriegsfeld LJ, Gibson EM, Williams W, et al. The roles of RFamide-related peptide-3 in mammalian reproductive function and behaviour. J Neuroendocrinol. 2010;22:692-700.
8. Pineda R, Garcia-Galiano D, Sanchez-Garrido M, et al. Characterization of the potent gonadotropin-releasing activity of RF9, a se-lectiveantagonistofRF-Amide-relatedpeptidesand neuropeptide FF receptors: physiological and pharmacological implications. Endocrinology. 2010;151:1902-1913.
9. Pineda R, Garcia-Galiano D, Sanchez-Garrido MA, et al. Charac-terizationofthe inhibitory rolesofRFRP3, the mammalian ortholog of GnIH, in the control of gonadotropin secretion in the rat: in vivo and in vitro studies. Am J Physiol Endocrinol Metab. 2010;299: E39-E46.
10. Rizwan MZ, Poling MC, Corr M, et al. RFamide-related peptide-3 receptor gene expression in GnRH and kisspeptin neurons and GnRH-dependent mechanism of action. Endocrinology. 2012;153: 3770-3779.
11. Kirby ED, Geraghty AC, Ubuka T, Bentley GE, Kaufer D. Stress increases putative gonadotropin inhibitory hormone and decreases luteinizing hormone in male rats. Proc Natl Acad Sci USA. 2009; 106:11324-11329.
12. Geraghty AC, Muroy SE, Zhao S, Bentley GE, Kriegsfeld LJ, Kaufer D. Knockdown of hypothalamic RFRP3 prevents chronic stress-induced infertility and embryo resorption. eLife. 2015;4:e04316.
13. Gouardères C, Kieffer BL, Zajac J-M. Opposite alterations of NPFF1 and NPFF2 neuropeptide FF receptor density in the triple MOR/DOR/KOR-opioid receptor knockout mouse brains. J Chem Neuroanat. 2004;27:119-128.
14. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and/3-endorphin. Science. 1981;213:1394-1397.
15. Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012;11:462-478.
16. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013;12:667-687.
17. Chalmers DT, Lovenberg T, De Souza E. Localization of novel cor-ticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995;15:6340-6350.
18. Post A, Ohl F, Almeida OF, et al. Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychophar-macology. 2005;180:150-158.
19. Smith GW, Aubry J-M, Dellu F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 1998;20:1093-1102.
20. Timpl P, Spanagel R, Sillaber I, et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet. 1998;19:162-166.
21. Kaewwongse M, Takayanagi Y, Onaka T. Effects of RFamide-related peptide (RFRP)-1 and RFRP-3 on oxytocin release and anxiety-related behaviour in rats. J Neuroendocrinol. 2011;23:20-27.
22. Simonin F, Schmitt M, Laulin J-P, et al. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA. 2006; 103:466-471.
23. Liu X, Herbison AE. RF9 excitation of GnRH neurons is dependent upon kiss1r in the adult male and female mouse. Endocrinology. 2014;155:4915-4924.
24. Findeisen M, Würker Cc, Rathmann D, et al. Selective mode of action of guanidine-containing non-peptides at human NPFF receptors. J Med Chem. 2012;55:6124-6136.
25. Maletínská L, Tichá A, Nagelová V, et al. Neuropeptide FF analog RF9 is not an antagonist of NPFF receptor and decreases food intake in mice after its central and peripheral administration. Brain Res. 2013;1498:33-40.
26. Rudolf K, Eberlein W, Engel W, et al. The first highly potent and selective non-peptide neuropeptide Y Y 1 receptor antagonist: BIBP3226. Eur J Pharmacol. 1994;271:R11-R13.
27. Aiglstorfer I, Hendrich I, Moser C, Bernhardt G, Dove S, Buschauer A. Structure-Activity relationships of neuropeptide YY 1 receptor antagonists related to BIBP 3226. Bioorg Med Chem Lett. 2000; 10:1597-1600.
28. Mollereau C, Mazarguil H, Quelven I, et al. Pharmacological characterization of human NPFF(1) andNPFF(2) receptors expressed in CHO cells by using NPY(1) receptor antagonists. Eur J Pharmacol. 2002;451:245-256.
29. Mollereau C, Gouardères C, Dumont Y, et al. Agonist and antagonist activities on human NPFF2 receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol. 2001;133:1-4.
30. Beltramo M, Robert V, Galibert M, et al. Rational designoftriazolo-lipopeptides analogsofkisspeptin inducingalong-lastingincrease of gonadotropins. J Med Chem. 2015;58(8):3459-3470.
31. Steyn F, Wan Y, Clarkson J, Veldhuis J, Herbison A, Chen C. Development of a methodology for and assessment of pulsatile lutein-izing hormone secretion in juvenile and adult male mice. Endocrinology. 2013;154:4939-4945.
32. García-Galiano D, van Ingen Schenau D, Leon S, et al. Kisspeptin signaling is indispensable for neurokinin B, but not glutamate, stimulation of gonadotropin secretion in mice. Endocrinology. 2011; 153:316-328.
33. Taniguchi H, He M, Wu P, et al. A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron. 2011;71:995-1013.
34. Wamsteeker Cusulin JIW, Füzesi T, Watts AG, Bains JS. Characterization of corticotropin-releasing hormone neurons in the para-ventricular nucleus of the hypothalamus of Crh-IRES-Cre mutant mice. PLoS One. 2013;8:e64943.
35. Caraty A, Blomenröhr M, Vogel G, Lomet D, Briant C, Beltramo M. RF9 powerfully stimulates gonadotrophin secretion in the ewe: evidence for a seasonal threshold of sensitivity. J Neuroendocrinol. 2012;24:725-736.
36. Ducret E, Anderson GM, Herbison AE. RFamide-related peptide-3, a mammalian gonadotropin-inhibitory hormone ortholog, regulates gonadotropin-releasing hormone neuron firing in the mouse. Endocrinology. 2009;150:2799-2804.
37. Mitra R, Sapolsky RM. Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proc Natl Acad Sci USA. 2008;105:5573-5578.
38. Wu C-H, Tao P-L, Huang EY-K. Distribution of neuropeptide FF (NPFF) receptors in correlation with morphine-induced reward in the rat brain. Peptides 2010;31:1374-1382.
39. Petraglia F, Sutton S, Vale W, Plotsky P. Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophy-sial-portal circulation. Endocrinology. 1987;120:1083-1088.
40. Rivest S, Plotsky P, Rivier C. CRF alters the infundibular LHRH secretory system from the medial preoptic area of female rats: possible involvement of opioid receptors. Neuroendocrinology. 1993; 57:236-246.
41. Rivier C, Vale W. Influence of corticotropin-releasing factor on re-productivefunctionsintherat. Endocrinology. 1984;114:914-921.